CytomX Therapeutics, Inc.
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
CTMX$1.980.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Stockholders’ Equity (Deficit)
(in thousands, except share data)
| Accumulated | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Additional · Other · Total | |||||||||
| Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders' | |||||||||
| Shares · Amount · Capital · Income (Loss) · Deficit · Equity (Deficit) | |||||||||
| Balance at December 31, 2024 | 80,099,889 | $1 | $691,095 | $27 | $(691,579) | $(456) | |||
| Exercise of stock options and release of RSUs | 521,404 | — | — | — | — | — | |||
| Stock-based compensation | — | — | 2,008 | — | — | 2,008 | |||
| Other comprehensive loss | — | — | — | (28) | — | (28) | |||
| Net income | — | — | — | — | 23,525 | 23,525 | |||
| Balance at March 31, 2025 | 80,621,293 | $1 | $693,103 | $(1) | $(668,054) | $25,049 | |||
| Exercise of stock options and release of RSUs | 332,741 | — | 76 | — | — | 76 | |||
| Issuance of common stock under the ESPP | 110,974 | — | 101 | — | — | 101 | |||
| Issuance of common stock in follow-on offering, net of issuance cost | 76,923,076 | 1 | 93,372 | — | — | 93,373 | |||
| Exercise of pre-funded warrants | 6,923,031 | — | — | — | — | — | |||
| Stock-based compensation | 1,431 | — | 1,431 | ||||||
| Other comprehensive loss | — | — | — | 34 | — | 34 | |||
| Net loss | — | — | — | — | (154) | (154) | |||
| Balance at June 30, 2025 | 164,911,115 | 2 | 788,083 | 33 | (668,208) | 119,910 | |||
| Accumulated | |||||||||
| Additional · Other · Total | |||||||||
| Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders' | |||||||||
| Shares · Amount · Capital · Income (Loss) · Deficit · Deficit | |||||||||
| Balance at December 31, 2023 | 67,310,838 | $1 | $675,905 | $95 | $(723,448) | $(47,447) | |||
| Exercise of stock options and release of RSUs | 826,797 | — | 174 | — | — | 174 | |||
| Stock-based compensation | — | — | 1,907 | — | — | 1,907 | |||
| Other comprehensive loss | — | — | — | (105) | — | (105) | |||
| Net income | — | — | — | — | 13,791 | 13,791 | |||
| Balance at March 31, 2024 | 68,137,635 | $1 | $677,986 | $(10) | $(709,657) | $(31,680) | |||
| Exercise of stock options and release of RSUs | 12,477 | — | 20 | — | — | 20 | |||
| Issuance of common stock under the ESPP | 196,930 | — | 236 | — | — | 236 | |||
| Issuance of common stock under the Open Market Sale Agreement, net of issuance cost | 2,270,608 | — | 4,843 | — | — | 4,843 | |||
| Exercise of pre-funded warrants | 7,499,951 | — | — | — | — | — | |||
| Stock-based compensation | — | — | 1,882 | — | — | 1,882 | |||
| Other comprehensive loss | — | — | — | 6 | — | 6 | |||
| Net loss | — | — | — | — | (6,534) | (6,534) | |||
| Balance at June 30, 2024 | 78,117,601 | $1 | $684,967 | $(4) | $(716,191) | $(31,227) | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.